Ligand Pharmaceuticals Stock (NASDAQ:LGND)


ForecastChart

Previous Close

$112.56

52W Range

$81.74 - $129.90

50D Avg

$108.07

200D Avg

$110.47

Market Cap

$2.19B

Avg Vol (3M)

$122.93K

Beta

0.71

Div Yield

-

LGND Company Profile


Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

68

IPO Date

Nov 18, 1992

Website

LGND Performance


Latest Earnings Call Transcripts


Q2 22Aug 08, 22 | 9:08 PM
Q1 22May 04, 22 | 6:57 PM
Q4 21Feb 17, 22 | 9:57 PM

Peer Comparison


TickerCompany
CYTKCytokinetics, Incorporated
GPCRStructure Therapeutics Inc.
ETNB89bio, Inc.
BGNEBeiGene, Ltd.
BPMCBlueprint Medicines Corporation
APLSApellis Pharmaceuticals, Inc.
RCUSArcus Biosciences, Inc.
ASNDAscendis Pharma A/S
AKROAkero Therapeutics, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
PASGPassage Bio, Inc.
ORICORIC Pharmaceuticals, Inc.